Effectiveness of interferon-beta therapy for recurrent glioblastoma: a case report

Satoshi Utsuki, Hidehiro Oka, Yoshiteru Miyajima, Kimitoshi Sato, Satoru Shimizu, Sachio Suzuki, and Kiyotaka Fujii

Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

ABSTRACT

Aims and background. Glioblastoma has a poor prognosis, with few therapeutic options if it recurs. We report a case in which we were able to inhibit the growth of a recurrent glioblastoma by weekly single-dose administration of interferon-beta.

Case report. A patient with recurrent glioblastoma after radiation and chemotherapy was treated with nimustine and interferon-beta. After 2 cycles of nimustine, the patient’s leukocyte, neutrophil, and platelet counts showed grade 4 toxicity according to the National Cancer Institute’s Common Toxicity Criteria. The patient was treated with a weekly single dose of interferon-beta at $6 \times 10^6$ IU. The tumor showed no remarkable changes after 18 months, and the patient’s Karnofsky performance status remained at 50%.

Conclusions. The administration of interferon-beta produced long-term control in one case of glioblastoma and may be an effective therapy. Free full text available at www.tumorionline.it